GSK Immune Drug Cleared by EU for Endometrial Cancer

GSK Plc said its new medicine Jemperli won clearance in the European Union for women with a form of endometrial cancer.

The immune-oncology treatment was approved in combination with chemotherapy for a subset of adult patients who have an accumulation of errors in genetic sequences, GSK said in a statement Monday. The EU also converted a conditional approval for Jemperli alone or after chemo into a full clearance.